Emergence of nalidixic acid-resistant Salmonella enterica serovar Typhi resistant to ciprofloxacin in India

References

1. Asna S. M., Haq J. A. 2000; Decrease of antibiotic resistance in Salmonella typhi isolated from patients attending hospitals of Dhaka City over a 3 year period. Int J Antimicrob Agents 16:249–251 [CrossRef]
   [Google Scholar]
2. Asna S. M., Haq J. A., Rahman M. 2003; Nalidixic acid-resistant Salmonella enterica serovar typhi with decreased susceptibility to ciprofloxacin caused treatment failure: a report from Bangladesh. Jpn J Infect Dis 56:32–33
   [Google Scholar]
3. Chiu C. H., Wu T. L., Su L. H., Chu C., Chia J. H., Kuo A. J., Chien M. S., Lin T. Y. 2002; The emergence in Taiwan of fluoroquinolone resistance in Salmonella enterica serotype cholerasuis . N Eng J Med 346:413–419 [CrossRef]
   [Google Scholar]
4. Hakanen A., Kotilainen P., Jalava J., Siitonen A., Huovienen P. 1999; Detection of decreased fluoroquinolone susceptibility in salmonellas and validation of nalidixic acid screening test. J Clin Microbiol 37:3572–3577
   [Google Scholar]
5. Jesudason M. V., Malathy B., John T. J. 1996; Trends of increasing levels of minimum inhibitory concentration (MIC) of ciprofloxacin to Salmonella typhi . Ind J Med Res 103:247–249
   [Google Scholar]
6. Kapil A. R., Das B. 2002; Nalidixic acid susceptibility test to screen ciprofloxacin resistance in Salmonella typhi . Ind J Med Res 115:49–54
   [Google Scholar]
7. Le Lostec Z., Fegueux S., Jouve P., Cheron M., Mornet P., Boisivon A. 1997; Reduced susceptibility to quinolones in Salmonella typhi acquired in Europe: a clinical failure of treatment. Clin Microbiol Infect 3:576–577 [CrossRef]
   [Google Scholar]
8. Marimon J. M., Goariz M., Zigorraga C., Cilla G., Perez-Trallero E. 2004; Increasing prevalence of quinolone resistance in human nontyphoid Salmonella enterica isolates obtained in Spain from 1981 to 2003. Antimicrob Agents Chemother 3:576–577
   [Google Scholar]
9. Mehta G., Randhawa V. S., Mohapatra N. P. 2001; Intermediate susceptibility to ciprofloxacin in Salmonella typhi strains in India. Eur J Clin Microbiol Infect Dis 20:760–761 [CrossRef]
   [Google Scholar]
10. Miller S. I., Hohmann E. L., Pegues D. A. 1995; Salmonella. In Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases . , 4th edn. pp  2013–2033 Edited by Mandell G. L., Bennett E., Dolin R. New York: Churchill Livingstone;
11. Murdoch D. A., Banatvala N. A., Bone A., Shoismatulloev B. I., Ward L. R., Threlfall E. J. 1998; Epidemic ciprofloxacin-resistant Salmonella typhi in Tajikistan. Lancet 351:339 [CrossRef]
    [Google Scholar]
12. Threlfall E. J., Ward L. R. 2001; Decreased susceptibility to ciprofloxacin in Salmonella enterica serotype typhi in the United Kingdom. Emerg Infect Dis 7:448–450 [CrossRef]
    [Google Scholar]
13. Threlfall E. J., Ward L. R., Skinner J. A., Smith H. R., Lacey S. 1999; Ciprofloxacin-resistant Salmonella typhi and treatment failure. Lancet 353:1590–1591 [CrossRef]
    [Google Scholar]
14. Threlfall E. J., Skinner J. A. S., Ward L. R. 2001; Detection of decreased in vitro susceptibility to ciprofloxacin in Salmonella enterica serotypes typhi and paratyphi A . J Antimicrob Chemother 48:740–741 [CrossRef]
    [Google Scholar]
15. Wain J., Hoa N. T., Chinh N. T., Vinn H., Everett M. J., Diep T. S., Day N. P., Solomon T., White N. J. other authors 1997; Quinolone-resistant Salmonella typhi in Vietnam: molecular basis of resistance and clinical response to treatment. Clin Infect Dis 25:1404–1410 [CrossRef]
    [Google Scholar]